NANJING, China, Aug. 25, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has received the new drug approval from the State Food and Drug Administration ("SFDA") for Iremod.
Iremod, which was independently developed by Simcere, will be the first Iguratimod drug on the global market. It is a new drug in the category of Disease Modifying Anti-rheumatic Drugs ("DMARDS"), and will be primarily used in the treatment of active rheumatoid arthritis. Clinical studies demonstrate that Iremod can significantly alleviate symptoms caused by active rheumatoid arthritis.
Mr. Ren Jinsheng, Chairman and Chief Executive Officer of Simcere, commented: "Bringing Iremod to the Chinese market will allow millions of patients suffering from active rheumatoid arthritis to enjoy higher quality treatment. Iremod will provide new and more effective options for doctors. This approval is a breakthrough for Simcere. We will continue to put our efforts and resources into developing and producing effective and innovative medicines for patients."
About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics. The Company has introduced an innovative anti-cancer medication Endu, first-to-market generics such as Bicun and Anxin, and a first-to-market medication Sinofuan. Simcere manufactures and sells drugs in the oncological, cardiovascular, anti-inflammatory and anti-infection therapeutical areas. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence or mortality rates and for which there is a clear demand for more effective pharmacotherapy including cancer and cardiovascular, cerebrovascular, inflammatory and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: email@example.comIn Nanjing:Yehong ZhangPresidentSimcere Pharmaceutical GroupTel: +86-25-8556-6666 ext 8811In Beijing:Yue YuBrunswick Group Tel: +86-10-5960-8600In the United States:Kate TellierBrunswick GroupTel: +1-212-333-3810In Hong Kong:Joseph Lo Chi-LunBrunswick GroupTel: +852-3512-5000
|SOURCE Simcere Pharmaceutical Group|
Copyright©2010 PR Newswire.
All rights reserved